ATRT-11. PREVALENCE OF GERMLINE VARIANTS IN SMARCB1 INCLUDING SOMATIC MOSAICISM IN AT/RT AND OTHER RHABDOID TUMORS. (4th December 2020)

• Record Type: Journal Article
• Authors: Shirai, Ryota; Osumi, Tomoo; Terashima, Keita; Kiyotani, Chikako; Uchiyama, Meri; Tsujimoto, Shinichi; Yoshida, Masanori; Yoshida, Kaoru; Uchiyama, Toru; Tomizawa, Daisuke; Shioda, Yoko; Sekiguchi, Masahiro; Watanabe, Kenichiro; Keino, Dai; Ueno-Yokohata, Hitomi; Ohki, Kentaro; Takita, Junko; Ito, Shuichi; Deguchi, Takao; Kiyokawa, Nobutaka; Ogiwara, Hideki; Hishiki, Tomoro; Ogawa, Seishi; Okita, Hajime; Matsumoto, Kimikazu; Yoshioka, Takako; Kato, Motohiro
• Is Part Of: Neuro-oncology. Volume 22(2020)Supplement 3
• Page Start: iii277
• Page End: iii278
• Publication Date: 2020-12-04
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa222.011
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: Genetic hallmark of atypical teratoid/rhabdoid tumor (AT/RT) is loss-of-function variants or deletions in SMARCB1 gene on 22q11.2 chromosome, which is common to extracranial malignant rhabdoid tumors (MRT). Previous studies demonstrated that approximately one-thirds of AT/RT and extracranial MRT patients harbored germline SMARCB1 variants as the rhabdoid tumor predisposing syndrome. We studied herein intensive analysis of the SMARCB1 gene in AT/RT and extracranial MRT patients focusing on prevalence of germline genetic variants. PROCEDURE: In total, 16 patients were included. Both tumor-derived DNA and germline DNA were obtained from all patients. First, screening for SMARCB1 alterations in the tumor specimens was done by direct sequencing, ddPCR and SNP array analysis. Then, analysis of germline DNA samples focusing on the genomic abnormalities detected in the paired tumors in each case was performed. RESULTS: In eight of 16 cases (50%), genomic alterations observed in the tumor-derived DNA were also detected in the germline DNA. It is worth noting that three patients had germline mosaicism. Two of three patients had mosaic deletion, including SMARCB1 region, and the average copy number of the deleted region in the SMARCB1 gene in the germline was 1.60 and 1.76. For another patient, the fraction of SMARCB1 variants in normal cells was as low as 1.7%. CONCLUSIONS: Approximately half the MRT cases in this study had SMARCB1 germline alterations. Considering the presence of low-frequency mosaicisms which conventional methods might overlook, inherited germline variants in predisposition genes are more important than previously assumed for the pathogenesis of pediatric cancers.